MAI Capital Management Purchases 28,163 Shares of Pfizer Inc. $PFE

MAI Capital Management grew its position in shares of Pfizer Inc. (NYSE:PFE) by 7.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 393,049 shares of the biopharmaceutical company’s stock after purchasing an additional 28,163 shares during the quarter. MAI Capital Management’s holdings in Pfizer were worth $10,015,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. RWA Wealth Partners LLC grew its holdings in Pfizer by 2.3% during the 3rd quarter. RWA Wealth Partners LLC now owns 237,439 shares of the biopharmaceutical company’s stock worth $6,050,000 after acquiring an additional 5,231 shares during the last quarter. Cary Street Partners Financial LLC lifted its holdings in shares of Pfizer by 6.8% during the third quarter. Cary Street Partners Financial LLC now owns 261,861 shares of the biopharmaceutical company’s stock worth $6,672,000 after purchasing an additional 16,705 shares during the period. Bradley Foster & Sargent Inc. CT grew its stake in shares of Pfizer by 12.5% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 587,805 shares of the biopharmaceutical company’s stock worth $14,977,000 after purchasing an additional 65,206 shares during the last quarter. JFS Wealth Advisors LLC grew its stake in shares of Pfizer by 10.4% in the third quarter. JFS Wealth Advisors LLC now owns 47,690 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 4,485 shares during the last quarter. Finally, Waddell & Associates LLC increased its holdings in Pfizer by 7.3% in the third quarter. Waddell & Associates LLC now owns 24,278 shares of the biopharmaceutical company’s stock valued at $619,000 after purchasing an additional 1,660 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.1%

Shares of NYSE PFE opened at $27.11 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $154.11 billion, a PE ratio of 19.93 and a beta of 0.47. The company’s fifty day simple moving average is $26.04 and its 200 day simple moving average is $25.37. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the firm posted $0.63 earnings per share. The business’s revenue was down 1.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA grants full approval to the BRAFTOVI (encorafenib) combination regimen for first‑line metastatic colorectal cancer with BRAF V600E mutation — a label expansion based on the Phase 3 BREAKWATER trial that de‑risks and commercializes a late‑stage oncology asset, supporting potential incremental sales and long‑term oncology upside. U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
• Positive Sentiment: Pfizer inks a China commercialization/licensing deal for Sciwind’s ecnoglutide (a next‑gen biased GLP‑1) with up to ~$495M in potential payments — accelerates Pfizer’s obesity/diabetes footprint in a large market and signals management’s push into metabolic medicines beyond acquisitions. Pfizer in diabetes drug deal with Sciwind Biosciences
• Positive Sentiment: Pipeline momentum: coverage notes highlight BREAKWATER results plus expanded obesity programs (Metsera acquisition and >20 weight‑management studies) — suggests diversification of future growth drivers beyond legacy products. Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results
• Positive Sentiment: Dividend support: coverage reiterates Pfizer’s high dividend yield (attractive income for some investors) and management’s commitment to the payout, which can cushion the stock in choppy markets. This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income
• Neutral Sentiment: Pneumococcal vaccine Phase 1 update in China — an early‑stage readout that is informational for the pipeline but unlikely to move top‑line revenue in the near term. Pfizer’s Pneumococcal Vaccine Study in China: What the Latest Trial Update Means for PFE Investors
• Neutral Sentiment: Valuation and performance write‑ups debate whether PFE is offering value after mixed multi‑year returns — useful context for long‑term investors but not an immediate catalyst. Is Pfizer (PFE) Offering Value After Mixed Multi Year Share Price Performance
• Negative Sentiment: Pfizer terminated a Phase 1b ulcerative colitis study — a setback for that early‑stage program and a reminder of R&D risk; impact on revenue is limited but it trims future optionality in immunology. Pfizer Terminates Early-Stage Ulcerative Colitis Drug Study: What Investors Should Watch
• Negative Sentiment: Analyst caution: commentary that Pfizer has underperformed the healthcare sector over the past year could pressure sentiment and limit upside until clearer organic growth or margin inflection is visible. Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Analysts Set New Price Targets

A number of research firms have commented on PFE. Zacks Research lowered Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Royal Bank Of Canada began coverage on Pfizer in a report on Tuesday. They issued an “underperform” rating and a $25.00 target price on the stock. HSBC reissued a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. UBS Group started coverage on shares of Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. Finally, Morgan Stanley decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $27.70.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.